WO2023213854 - CRYSTALLINE FORM OF 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL (S)-1-(PYRIDAZIN-3-YLCARBAMOYL)-6 AZASPIRO[2.5]OCTANE-6-CARBOXYLATE AS MONOACYLGLYCEROL LIPASE INHIBITOR.
National phase entry:
Publication Number
WO/2023/213854
Publication Date
09.11.2023
International Application No.
PCT/EP2023/061626
International Filing Date
03.05.2023
Title **
[English]
CRYSTALLINE FORM OF 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL (S)-1-(PYRIDAZIN-3-YLCARBAMOYL)-6 AZASPIRO[2.5]OCTANE-6-CARBOXYLATE AS MONOACYLGLYCEROL LIPASE INHIBITOR.
[French]
FORME CRISTALLINE DE 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL (S)-1-(PYRIDAZINE-3-YLCARBAMOYL)-6 AZASPIRO [2,5] OCTANE-6-CARBOXYLATE EN TANT QU'INHIBITEUR DE LA MONOACYLGLYCÉROL LIPASE
Applicants **
H. LUNDBECK A/S
Ottiliavej 9
2500 Valby, DK
Inventors
VETTER, Thomas
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
WIENER, John J.M.
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
GRICE, Cheryl A.
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
BUZARD, Daniel J.
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
CISAR, Justin S.
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
WEBER, Olivia D.
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
ALLAN, Amy
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
RAFFAELE, Nicholas
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
MOODY, Jeanne V.
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
SHAGHAFI, Michael B.
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
Priority Data
63/338,252
04.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1184 | |
| EPO | Filing, Examination | 4743 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3310 |
Total: 10403 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Described herein is new crystalline forms of the MAGL inhibitor 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1- (pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.[French]
L'invention concerne de nouvelles formes cristallines de l'inhibiteur de MAGL 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(pyridazine-3-ylcarbamoyl)-6-azaspiro [2,5] octane-6-carboxylate.